Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus

EU orphan designation number: EU/3/15/1440   
Active ingredient: Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus
Indication: Treatment of Epstein-Barr virus infection following haematopoietic stem cell transplantation
Sponsor: Miltenyi Biotec GmbH
Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
23/03/2015 Orphan designation EMA/OD/247/14 (2015)2015 of 19/03/2015